Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity
- PMID: 489967
Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity
Abstract
Immunotherapy with a combination of Corynebacterium parvum and specific heteroantiserum is significantly more effective than treatment with either single agent in prolonging the survival of mice that have recevied an i.p. injection of syngeneic murine ovarian carcinoma (MOT) cells. Invitro, a combination of C. parvum-activated peritoneal cells and specific heteroantiserum has proven significantly more effective than either single component in destroying 51Cr-labeled MOT cells in the absence of complement. Activation of peritoneal cells to produce lysis of tumor in the presence specific antiserum peaked 3 to 7 days after a single injection of C. parvum and declined to baseline over 3 to 4 weeks. With repeated i.p. injections of C. parvum at appropriate intervals, activation of peritoneal cells could be prolonged and augmented. Among the routes tested, only i.p. administration of C. parvum was effective, although activation of peritoneal cells for cooperation with heteroantiserum was observed over a broad range of i.p. dosage (0.45 to 4.20 mg). These data suggest that the administration of C. parvum by appropriate doses, routes, and schedules can attract and activate a population of peritoneal effectors that mediate antibody-dependent cytotoxicity more effectively than resident peritoneal cells.
Similar articles
-
Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.Cancer Res. 1983 Mar;43(3):1395-401. Cancer Res. 1983. PMID: 6825108
-
Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity.J Immunol. 1984 Jul;133(1):519-26. J Immunol. 1984. PMID: 6373934
-
Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.Cancer Res. 1984 Nov;44(11):5118-23. Cancer Res. 1984. PMID: 6488171
-
Serotherapy of ovarian cancer.Nat Immun Cell Growth Regul. 1988;7(4):193-215. Nat Immun Cell Growth Regul. 1988. PMID: 3070370 Review.
-
Immunologic approaches to the management of ovarian carcinoma.Semin Oncol. 1984 Sep;11(3):264-74. Semin Oncol. 1984. PMID: 6207593 Review. No abstract available.
Cited by
-
Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.Clin Chem. 2013 Jan;59(1):22-31. doi: 10.1373/clinchem.2012.187047. Epub 2012 Nov 30. Clin Chem. 2013. PMID: 23204222 Free PMC article. No abstract available.
-
Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions.Cancer Immunol Immunother. 1994 Jan;38(1):23-30. doi: 10.1007/BF01517166. Cancer Immunol Immunother. 1994. PMID: 8299115 Free PMC article.
-
Antibody-dependent cellular cytotoxicity-mediated serotherapy against murine neuroblastoma. I. In vitro and in vivo treatment using normal, gamma-irradiated and immune-stimulated rat effector cells.Cancer Immunol Immunother. 1982;14(2):117-23. doi: 10.1007/BF00200179. Cancer Immunol Immunother. 1982. PMID: 6765619 Free PMC article.
-
Role of activated macrophages in antibody-dependent lysis of tumor cells.J Exp Med. 1980 Jul 1;152(1):183-97. doi: 10.1084/jem.152.1.183. J Exp Med. 1980. PMID: 6995552 Free PMC article.
-
Reactivity of a monoclonal antibody with human ovarian carcinoma.J Clin Invest. 1981 Nov;68(5):1331-7. doi: 10.1172/jci110380. J Clin Invest. 1981. PMID: 7028788 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources